Trial Profile

Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Coramitug (Primary)
Indications Transthyretin-related hereditary amyloidosis
Focus Therapeutic Use
Sponsors Novo Nordisk

Most Recent Events

25 Jun 2025 Status changed from active, no longer recruiting to completed.
08 May 2025 According to a Prothena media release, trial has completed enrollment with trial completion in 1H 2025 and results expected in 2H 2025.
29 Apr 2025 Planned End Date changed from 19 May 2025 to 13 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com